Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8,
non responders will be discontinued, partial responders will be given add-on Enstilar QD for
4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16.